Organs-on a chip technology: potential and applications
A liver-on-a-chip that reveals drug metabolism without human testing; a brain-on-a-chip to screen neurotherapeutics without exposing patients; or a kidney-on-a-chip that reproduces filtration, reabsorption and excretion to refine renal toxicity assessment. These examples highlight how organ-on a chip technology provides advanced, human-relevant models for biomedical research. Beyond medicine, organ-on a chip technology is also emerging as a powerful platform to evaluate the safety, efficacy and functionality of compounds across industrial sectors. By precisely mimicking human organ functions, it enables more predictive, animal-free studies.Food applications: bioaccessibility, metabolism and microbiota
In food science, intestine-on-a-chip models simulate the digestive process and the absorption of nutrients or functional ingredients along the gastrointestinal tract. This is key to:- Studying bioavailability of bioactives (polyphenols, probiotics, vitamins, peptides).
- Analysing interactions with the intestinal microbiota under dynamic, controlled conditions.
- Evaluating potential inflammatory or immunomodulatory effects of novel ingredients.
Cosmetic applications: sustainability, dermal safety and active-ingredient efficacy
In cosmetics, organ-on a chip technology offers a breakthrough to assess dermal toxicity, efficacy of active ingredients, and their interaction with human skinwithout animal testing. Skin-on-a-chip models reproduce key skin layers and functions (epidermal barrier, local immune response, vascularisation), enabling:- Assessment of skin irritation/sensitisation in new formulas.
- Studies on transdermal penetration and behaviour of nanomaterials or encapsulated actives.
- Real-time efficacy readouts for antioxidants, peptides or UV filters under simulated physiological conditions.
Pharmaceutical applications: faster development and personalised medicine
Organ-on a chip technology is reshaping drug R&D. Microfluidic systems simulate complex human physiologycirculation, hepatic metabolism, bloodbrain barrierin controlled, reproducible environments, enabling teams to:- Evaluate pharmacokinetics/pharmacodynamics early.
- Study hepatic, renal and cardiac toxicity with greater human relevance than animal models.
- Test efficacy in simulated disease states (e.g., fatty liver, inflamed intestine).
- Advance personalised medicine using patient-derived cells to anticipate individual responses.
Funded by the aid program for hiring young professionals specialized in internationalization
